Neuren Pharmaceuticals (NEU AU): Record 2Q Daybue Sales; Guidance Upgraded; Pipeline Holds Key
Neuren’s Daybue reported 2Q26 revenue of $125M, up 30% YoY and 24% QoQ, which is the highest quarterly sales. The company has raised anticipated...
88 Views
APAC Healthcare Weekly (Oct 4) – Hengrui, Hansoh, Chugai Pharma, Daiichi Sankyo, Otsuka, Sun Pharma
Hengrui stuck $2.6B outlicensing deal with Novo. EC revoked EU marketing authorization of Hansoh’s aumolertinib. Otsuka initiates NDA submission to...
97 Views
Primer: Neuren Pharmaceuticals (NEU AU) - Aug 2026
Neuren Pharmaceuticals has successfully transitioned to a commercial-stage entity, driven by the strong sales of its first-in-class treatment...
92 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
​Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
872 Views
APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma
CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...
103 Views